Quark Pharmaceuticals Inc

Quark Pharmaceuticals Inc is located in Newark, United States on 7999 Gateway Blvd Suite 310. Quark Pharmaceuticals Inc is rated 3 out of 5 in the category pharmaceutical companypharmacy in United States. Quark Pharmaceuticals About Us About Us Executive Management Senior Management RiboQuark Joint Venture Quark Timeline Pipeline Pipeline QPI-1002 QPI-1007 PF-655 Technology Technology Publications Partners Partners Scientific Collaborations Intellectual Property Intellectual Property IP Announcements News News Events Contact Contact Careers Loading... Welcome to Quark An RNAi- based, late stage clinical company Check Our Phase III pivotal studies Vertically integrated From gene discovery to novel therapeutics Learn More Strong pipeline Of clinical and preclinical product candidates Check Pipeline Freedom to operate In the nucleic acid intellectual property space Read More On Our Intellectual Property ­ Quark Home Page eyal 2015-09-01T12:09:27+00:00 Our Leading Products QPI-1002 Phase III QPI-1007 Phase III PF-655 Phase II Check Pipeline Latest News eyal 2018-10-22T12:43:17+00:00 Quark Pharmaceuticals Announces Acceptance of Presentation and Abstracts at ASN 2018 (October 23-28, 2018) and AAO 2018 (October 27-30, 2018) Annual Meetings October 22nd, 2018 eyal 2018-07-09T12:02:03+00:00 Quark Pharmaceuticals, Inc Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery July 9th, 2018 Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is a leader in the discovery and development of novel RNAi-based therapeutics. Events eyal 2018-10-22T12:43:17+00:00 Quark Pharmaceuticals Announces Acceptance of Presentation and Abstracts at ASN 2018 (October 23-28, 2018) and AAO 2018 (October 27-30, 2018) Annual Meetings eyal 2017-11-07T10:50:08+00:00 Quark Pharmaceuticals, Inc. to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference eyal 2017-11-05T12:03:27+00:00 Quark Pharmaceuticals, Inc. Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting Technology We have a fully integrated Research and Development team with a proven track record of translating our innovations in RNAi therapeutics from the bench to the clinic. We have full capabilities in the areas of cell and molecular biology, protein biochemistry, monoclonal antibody technology, bioinformatics, animal pharmacology, histopathology including immunohistochemistry and in situ hybridization, and drug delivery. Our development teams, to-date have progressed three drug candidates through four INDs into clinical studies in five different disease indications. About Quark Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is a leader in the discovery and development of novel RNAi-based therapeutics. Contact Info Headquarters Quark Pharmaceuticals, Inc. USA 7999 Gateway Boulevard, Suite 310 Newark, CA 94560 Phone: 510.402.4020 Fax: 510.402.4021 Email: [email protected] Research QBI Enterprises, Ltd. Weizmann Science Park, P.O.B. 4071 Ness Ziona, 70400, Israel. Phone: 972-8-9305-111 Fax: 972-8-9406-476 E-mail: [email protected] Human Resource For US operations: [email protected] For Israel operations: [email protected] Business Development Juliana Friedman Email: [email protected] Categories Events News Open Positions In Israel Patents Terms Of Use Terms of Use Copyright Info Privacy Policy Copyright 2020 Quark | All Rights Reserved